Literature DB >> 8262628

Conformationally appropriate expression of the Toxoplasma antigen SAG1 (p30) in CHO cells.

K Kim1, R Bülow, J Kampmeier, J C Boothroyd.   

Abstract

The Toxoplasma gondii major surface antigen, called SAG1 or p30, is a highly immunogenic protein which has generated great interest as a diagnostic reagent, as a potential subunit vaccine, and for its role in invasion. Unfortunately, bacterial recombinant protein is grossly misfolded so that, for example, it is not effectively recognized by antibodies to native SAG1. To overcome this, we have turned to expression in CHO cells, using cotransfection of the SAG1 gene and the mouse dihydrofolate reductase (DHFR) gene into CHO cells that are DHFR-. SAG1 expression was amplified by methotrexate coselection of CHO cells in combination with fluorescence-activated cell sorting for SAG1 expression. The resulting population expressed recombinant SAG1 that is recognized by antiserum specific for natural, nonreduced SAG1, indicating that, unlike in bacteria, expression in CHO cells results in proper folding. Processing was at least partially correct in that, like natural SAG1, recombinant SAG1 was attached to the plasma membrane via a glycolipid anchor, although tunicamycin treatment was necessary to prevent N-glycosylation (SAG1 is not glycosylated in the parasite but does have a consensus N-linked site). Finally, purified recombinant SAG1 was recognized by human sera known to be reactive to toxoplasma proteins, indicating that this material has potential as a diagnostic reagent and possibly as a component of a subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262628      PMCID: PMC186087          DOI: 10.1128/iai.62.1.203-209.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  Mammalian glycosylation mutants as tools for the analysis and reconstitution of protein transport.

Authors:  A W Brändli
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

2.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

Review 3.  Glycolipid anchoring of plasma membrane proteins.

Authors:  G A Cross
Journal:  Annu Rev Cell Biol       Date:  1990

4.  Evidence for glycosyl-phosphatidylinositol anchoring of Toxoplasma gondii major surface antigens.

Authors:  S Tomavo; R T Schwarz; J F Dubremetz
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

5.  Toxoplasma antigens recognized by human immunoglobulin A antibodies.

Authors:  J Huskinson; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

6.  The major surface antigen, P30, of Toxoplasma gondii is anchored by a glycolipid.

Authors:  S D Nagel; J C Boothroyd
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

7.  Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes.

Authors:  R Bülow; J C Boothroyd
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

8.  A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice.

Authors:  I A Khan; K H Ely; L H Kasper
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

9.  Toxoplasma antigens recognized by immunoglobulin G subclasses during acute and chronic infection.

Authors:  J Huskinson; P N Stepick-Biek; F G Araujo; P Thulliez; Y Suzuki; J S Remington
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

10.  Mannosamine, a novel inhibitor of glycosylphosphatidylinositol incorporation into proteins.

Authors:  M P Lisanti; M C Field; I W Caras; A K Menon; E Rodriguez-Boulan
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  13 in total

1.  Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Xiao Teng Ching; Mun Yik Fong; Yee Ling Lau
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

2.  Production of the main surface antigen of Toxoplasma gondii in tobacco leaves and analysis of its antigenicity and immunogenicity.

Authors:  Marina Clemente; Roberto Curilovic; Alina Sassone; Alicia Zelada; Sergio O Angel; Alejandro N Mentaberry
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

3.  Sensitive and specific identification of Neospora caninum infection of cattle based on detection of serum antibodies to recombinant Ncp29.

Authors:  Daniel K Howe; Keliang Tang; Patricia A Conrad; Karen Sverlow; J P Dubey; L David Sibley
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

4.  Conformationally correct expression of membrane-anchored Toxoplasma gondii SAG1 in the primitive protozoan Giardia duodenalis.

Authors:  Matthias Marti; Yajie Li; Peter Köhler; Adrian B Hehl
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

Authors:  H V Nielsen; S L Lauemøller; L Christiansen; S Buus; A Fomsgaard; E Petersen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies.

Authors:  D Harning; J Spenter; A Metsis; J Vuust; E Petersen
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

7.  Recombinant antigens to detect Toxoplasma gondii-specific immunoglobulin G and immunoglobulin M in human sera by enzyme immunoassay.

Authors:  D Aubert; G T Maine; I Villena; J C Hunt; L Howard; M Sheu; S Brojanac; L E Chovan; S F Nowlan; J M Pinon
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

8.  Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans.

Authors:  Pavlo Maksimov; Johannes Zerweck; Aline Maksimov; Andrea Hotop; Uwe Gross; Uwe Pleyer; Katrin Spekker; Walter Däubener; Sandra Werdermann; Olaf Niederstrasser; Eckhardt Petri; Marc Mertens; Rainer G Ulrich; Franz J Conraths; Gereon Schares
Journal:  Clin Vaccine Immunol       Date:  2012-04-11

9.  Nanoscale analysis reveals no domain formation of glycosylphosphatidylinositol-anchored protein SAG1 in the plasma membrane of living Toxoplasma gondii.

Authors:  Yuna Kurokawa; Tatsunori Masatani; Rikako Konishi; Kanna Tomioku; Xuenan Xuan; Akikazu Fujita
Journal:  Histochem Cell Biol       Date:  2019-09-21       Impact factor: 4.304

10.  Evaluation of recombinant dense granule antigen 7 (GRA7) of Toxoplasma gondii for detection of immunoglobulin G antibodies and analysis of a major antigenic domain.

Authors:  D Jacobs; M Vercammen; E Saman
Journal:  Clin Diagn Lab Immunol       Date:  1999-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.